In cooperation with RIKEN research institution, Kazan Federal University will start a ground-breaking study of polymorphisms in Russian population, which are the variations of genome influencing human sensitivity to drugs and other bioeffects.  According to Oleg Gusev, leading research fellow of the Institute of Fundamental Medicine and Biology, the only one existing polymorphism reference data base is the list approved by the US FDA.

Russia lacks this systematized data. Japan, for example, is facing the same problem and genotyping assay is being conducted in several clinics on a voluntary basis. The main obstacle that remains is genetic ethnic-bound peculiarities since there are over 185 ethnic groups currently residing in Russian Federation.

To tackle this problem Russian clinics will launch Pharmaco-FANTOM program, and combine their efforts to examine pharmaceutical genetics of different nationalities.